Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atezolizumab + navoximod
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination therapy consisting of atezolizumab, a PD-L1 inhibitor, and navoximod, an orally available small molecule inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1). This combination targets two complementary immune pathways: atezolizumab blocks PD-L1, preventing it from binding to PD-1 receptors on T cells, while navoximod inhibits IDO1, an enzyme that depletes tryptophan and produces kynurenine in the tumor microenvironment, which suppresses T cell function.
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)IDO1 (Indoleamine 2,3-dioxygenase 1)
Beyond the preview
Go deeper on atezolizumab + navoximod.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atezolizumab + navoximod.